Shares of Albireo Pharma Inc (NASDAQ:ALBO) have been assigned a consensus recommendation of “Buy” from the eight brokerages that are currently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, six have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price target among brokers that have covered the stock in the last year is $57.75.

ALBO has been the topic of a number of recent research reports. BidaskClub upgraded shares of Albireo Pharma from a “strong sell” rating to a “sell” rating in a report on Thursday, January 31st. ValuEngine upgraded shares of Albireo Pharma from a “hold” rating to a “buy” rating in a report on Thursday, February 28th. HC Wainwright initiated coverage on shares of Albireo Pharma in a report on Thursday, February 28th. They issued a “buy” rating and a $62.00 target price on the stock. Wedbush set a $69.00 target price on shares of Albireo Pharma and gave the company a “buy” rating in a report on Sunday, March 10th. Finally, Zacks Investment Research lowered shares of Albireo Pharma from a “hold” rating to a “sell” rating in a report on Monday, March 11th.

NASDAQ ALBO traded down $2.63 during trading hours on Monday, reaching $31.96. The company’s stock had a trading volume of 41,941 shares, compared to its average volume of 36,582. The stock has a market cap of $416.12 million, a price-to-earnings ratio of -8.11 and a beta of 1.72. Albireo Pharma has a fifty-two week low of $19.10 and a fifty-two week high of $37.95.

Albireo Pharma (NASDAQ:ALBO) last issued its quarterly earnings data on Thursday, March 7th. The biopharmaceutical company reported ($1.34) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.16) by ($0.18). The business had revenue of $0.57 million during the quarter, compared to analyst estimates of $1.94 million. Albireo Pharma had a negative net margin of 361.94% and a negative return on equity of 32.42%. On average, analysts predict that Albireo Pharma will post -5.74 earnings per share for the current year.

A number of large investors have recently added to or reduced their stakes in ALBO. Wells Fargo & Company MN lifted its holdings in shares of Albireo Pharma by 315.3% during the 3rd quarter. Wells Fargo & Company MN now owns 4,676 shares of the biopharmaceutical company’s stock worth $154,000 after acquiring an additional 3,550 shares during the period. Prudential Financial Inc. lifted its holdings in shares of Albireo Pharma by 9.0% during the 3rd quarter. Prudential Financial Inc. now owns 25,152 shares of the biopharmaceutical company’s stock worth $829,000 after acquiring an additional 2,075 shares during the period. Bank of New York Mellon Corp lifted its holdings in shares of Albireo Pharma by 8.6% during the 3rd quarter. Bank of New York Mellon Corp now owns 35,023 shares of the biopharmaceutical company’s stock worth $1,154,000 after acquiring an additional 2,760 shares during the period. BlackRock Inc. lifted its holdings in shares of Albireo Pharma by 11.4% during the 3rd quarter. BlackRock Inc. now owns 584,177 shares of the biopharmaceutical company’s stock worth $19,255,000 after acquiring an additional 59,901 shares during the period. Finally, Dimensional Fund Advisors LP lifted its holdings in shares of Albireo Pharma by 518.1% during the 3rd quarter. Dimensional Fund Advisors LP now owns 82,833 shares of the biopharmaceutical company’s stock worth $2,730,000 after acquiring an additional 69,431 shares during the period. Institutional investors own 66.85% of the company’s stock.

About Albireo Pharma

Albireo Pharma, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal (GI) disorders in the United States. Its lead product candidate is A4250, an orally administered ileal sodium dependent bile acid transporter (IBAT) inhibitor that is in phase III clinical trial for treating progressive familial intrahepatic cholestasis and phase II clinical trial for treating biliary atresia, alagille syndrome, and other cholestatic liver diseases.

Featured Story: Why do companies engage in swaps?

Analyst Recommendations for Albireo Pharma (NASDAQ:ALBO)

Receive News & Ratings for Albireo Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albireo Pharma and related companies with MarketBeat.com's FREE daily email newsletter.